Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.
Actively Recruiting
Researchers are evaluating the addition of pembrolizumab, a type of immunotherapy, to standard chemotherapy for patients with stage IIA, IIB, IIIA, or IIIB non-small cell lung cancer NSCLC that has been completely removed by surgery. This phase III trial aims to compare disease-free survival and overall survival between different treatment approaches, including chemotherapy alone and chemotherapy combined with pembrolizumab. The study also investigates side effects, drug discontinuation rates, quality of life, and specific biomarkers such as PD-L1 expression and tumor mutational burden. Participants are randomly assigned to one of two treatment groups. Both groups initially receive one of four chemotherapy regimens every 21 days for four cycles, chosen by their doctor. In one group, pembrolizumab is given after chemotherapy as an intravenous infusion every 21 days for up to 17 cycles or every 6 weeks for up to 16 cycles. In the other group, pembrolizumab is given together with chemotherapy during the initial cycles and then continued as monotherapy. Patients undergo various scans and blood tests throughout the study, including echocardiograms, MRIs, CT scans, and blood sample collections. During the trial, participants are closely monitored for disease status and side effects. Follow-up visits occur six weeks after treatment, then every three months for two years, every six months for years two to four, and annually for up to ten years after randomization. Quality of life questionnaires and symptom assessments are also completed. The main measure of success is disease-free survival, tracked for up to five years after enrollment. Safety and overall survival are reviewed for up to ten years to ensure long-term monitoring.
Actively Recruiting
Researchers are evaluating treatments for prostate cancer patients who have experienced a return of cancer markers biochemical recurrence after prostate surgery. This phase III trial compares whether adding enhanced therapy apalutamide with abiraterone and prednisone to standard care radiation therapy and short-term hormone therapy improves outcomes for patients without signs of cancer spread outside the pelvis. For patients with evidence of cancer spread beyond the pelvis detected by PET imaging, the study also tests whether adding targeted radiation to enhanced therapy provides additional benefit. Participants undergo baseline PET scans to identify the presence or absence of cancer spread outside the pelvis. Based on these results, they are randomly assigned to one of four treatment groups involving combinations of standard external radiation therapy, androgen deprivation therapies such as goserelin, leuprolide, triptorelin, relugolix, or degarelix, apalutamide taken daily by mouth, and for some, additional targeted radiation to metastatic sites. Treatments generally continue for six months unless disease progression or side effects occur. Patients may undergo additional PET imaging during the study to monitor response. Throughout the trial, participants will have regular follow-up visits every three months for two years, then every six months for years three to five, and annually up to ten years. Assessments include imaging scans, blood tests for prostate-specific antigen PSA, and quality-of-life evaluations using standardized questionnaires focusing on fatigue, pain, and cognitive function. Researchers will measure progression-free survival, overall survival, incidence of side effects, and quality of life up to ten years after treatment begins.